To prepare adequate healthcare measures in the case of a pandemic, vast numbers of people must be tested in order to understand the dynamics and behavior of the infection cycle. The medical staff working under extreme circumstances need basic but reliable laboratory supplies to help contain the pandemic. Read this special report to discover two solutions for COVID-19 patient testing that comply with guidelines from the US Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO). The…
Wednesday, September 15, 2021 Daily Archives
Accelerating the Development and Manufacture of Therapeutics Using the Octet Platform
The high costs of therapeutic discovery, development, and manufacture require improved process efficiencies and economics. Analytical tools that eliminate the need for reagent labeling and enable real-time data visualization save development time and improve efficiencies during process development. The Octet biolayer interferometry (BLI) platform and assays can be used throughout process development and manufacturing, including cell-line development, clone selection, and dynamic binding capacity (DBC) determination for affinity purification columns. The ability of the Octet BLI platform to monitor binding interactions…
CureVac drops CDMOs but continues COVID-19 vaccine development
CureVac has terminated contracts with two of its CDMOs – Wacker and Celonic – after demand for potential COVID-19 vaccine diminishes. However, the firm remains positive future clinical trials will go ahead. The German biotech entered the COVID-19 vaccine race in March 2020 and began creating mRNA COVID-19 candidate, CVnCoV. The firm quickly struck deals with various contract development manufacturing organizations (CDMOs) such as Novartis, Bayer, Rentschler, GSK, Wacker and Celonic to support production of the candidate. However, just a few…